73 results about "Distinctin" patented technology

The invention belongs to the technical field of biology, and particularly relates to a pleurotus citrinopileatus strain and application, the pleurotus citrinopileatus strain is JAUP10L and preserved in the China Center for Type Culture Collection on April 19, 2024, the preservation number is CCTCC NO: M2024720, and the pleurotus citrinopileatus strain is classified and named as Pleurotus citrinopileatus. The Pleurotus citrinopileatus strain JAUP10L has a pileus polymerization state which is obviously different from a variety in production, has the potential of being developed into a new variety, and enriches the variety of Pleurotus citrinopileatus.

The present disclosure provides for endonuclease enzymes having distinguishing domain features, as well as methods of using such enzymes or variants thereof.

The invention relates to a small molecule detection method. The method comprises the following steps: forming a multi-component compound containing'a first compound antibody-small molecules / small molecule binding partner compound-a second compound antibody ', and detecting the small molecules in a sample by detecting the multi-component compound, the micromolecule binding partner can be specifically bound with micromolecules, has at least two antigen binding sites, and can be bound with at least two micromolecules to obtain the micromolecule / micromolecule binding partner compound. And forming at least two new conformational epitopes different from the small molecule in the free state and the small molecule binding partner in the free state; each of the first complex antibody and the second complex antibody specifically binds to at least one new conformational epitope, and neither the first complex antibody nor the second complex antibody is an antibody of the small molecule antigen nor a specific antibody of the small molecule binding partner.

The invention discloses a compound enzyme additive for ruminant feed as well as a preparation method and application thereof, and relates to the technical field of feed. The additive comprises an edible hard shell, wherein an indicator is contained in the hard shell; the ruminant food indicator has the advantages that the ruminant food is often required to be ruminated into the oral cavity again for chewing due to insufficient chewing during primary feeding of the ruminant, so that the indicator breaking condition during primary chewing of the ruminant animal is reduced by wrapping the indicator with the hard shell, the number of broken additives is low when the ruminant animal has ruminant obstacles, and the ruminant food indicator is safe and reliable. Therefore, the quantity of the indicator exposed in the excrement is small, and the sick animal can be effectively distinguished from other animals.

The application discloses a preparation method of an immune protein extract of colostrum with tumor inhibition efficacy, and comprises the following steps: (1) raw material selection; (2) flocculation of casein; (3) sugar removal; (4) ultrafiltration membrane filtration; (5) directional hydrolysis; (6) cation exchange resin adsorption; (7) desalination; and (8) freeze drying. The extract of the application is rich in hydrophobic amino acid and alkaline amino acid hydrolysis fragments of the immune protein of colostrum, and has stronger antioxidant, immune enhancement and tumor inhibition activities. Different from common immune proteins of colostrum, the extract plays the anti-tumor activity as a result of the combined action of its double effects of immune enhancement and tumor cell growth inhibition.

The invention provides a prawn disease-oriented intestinal tract key metabolite design method and device, and relates to the technical field of strategy optimizing.The prawn disease-oriented intestinal tract key metabolite design method comprises the steps that prawn intestinal tract metabolite data are obtained, a random forest model distinguishes prawn health conditions through intestinal tract metabolite, and indication intestinal tract metabolite for distinguishing the health conditions is determined; the importance of the distinguishing metabolites is quantified through an MDA algorithm, and the most important distinguishing metabolite combination is screened; and distinguishing the metabolite and converting the metabolite concentration into a weighted undirected network, obtaining the feature vector centrality of each metabolite in the molecular ecological network, and determining a key metabolite. According to the invention, the random forest and the molecular ecological network are combined to identify key metabolites in a disease state, and the relative importance of each variable to a classification result is quantified. Meanwhile, the proportion of each key metabolite is determined by tracing back to healthy prawn intestinal tracts, and diseases are prevented and controlled symptomatically by compensating the combination of the inhibited key metabolite in the disease prawns.

The invention belongs to the technical field of biology, relates to a zearalenone degrading enzyme, and particularly relates to a bacillus subtilis source zearalenone degrading enzyme, an engineering strain thereof and an enzyme preparation prepared from the bacillus subtilis source zearalenone degrading enzyme. Compared with the known zearalenone degrading enzyme, the zearalenone degrading enzyme not only has obvious structure and sequence differences, but also shows an excellent degrading effect at low concentration. The lactone hydrolase derived from bacillus is found for the first time, and the biological resource basis of zearalenone degrading enzyme is expanded. The enzyme not only has significant difference from other degrading enzymes in structure, but also shows unique characteristics in degradation mechanism. The capability of efficiently degrading zearalenone shows that the bacillus subtilis has a wide application prospect in the fields of agriculture, food industry and the like. In addition, the invention also covers the structure of a degradation product generated by the zearalenone enzyme, and provides a new perspective for understanding a zearalenone degradation mechanism.

The invention provides an application of ginseng oil body in preparation of a medicine for preventing and / or treating colitis, and belongs to the technical field of ginseng seed oil. The detection shows that the oil core structure of the ginseng oil body mainly consists of oleic acid and linoleic acid, and is different from the triglyceride core of the oil body obtained from the existing oil crops. Through lipidomics detection and analysis, the phospholipid monomolecular layer has 335 phospholipids (positive ion mode) and 269 phospholipids (negative ion mode). Through proteomics detection and analysis, 24 kinds of Panax proteins are identified. The condition that the oil core of the ginseng oil body contains protopanaxatriol (PPT) is identified through high performance liquid chromatography-high resolution mass spectrometry. In-vitro detection shows that the ginseng oil body has anti-inflammatory and anti-oxidation effects.

The invention relates to an immobilization method and application of an alpha-amino acid ester acyltransferase immobilized enzyme, and belongs to the technical field of biological enzymes. In order to solve the problems of poor immobilization and difficulty in removing miscellaneous enzymes in the prior art, the invention provides an immobilization method of an alpha-amino acid ester acyltransferase immobilized enzyme, which comprises the following steps: under the catalytic action of a TG enzyme, carrying out enzyme protein cross-linking immobilization reaction on alpha-amino acid ester acyltransferase containing a plurality of glutamine residues and gelatin to obtain the alpha-amino acid ester acyltransferase immobilized enzyme. The immobilized alpha-amino acid ester acyltransferase immobilized enzyme is obtained. According to the present invention, the TG enzyme can well catalyze the glutamine residue and the lysine residue of the target protein to form the cross-linking reaction, and other miscellaneous enzymes are distinguished so as to avoid the reaction of the miscellaneous enzymes and gelatin, such that the good selectivity and the good specificity are provided, and the purification purpose can be easily achieved.

The application discloses a kind of recombinant Pichia pastoris for indirectly surface display PETase protein, comprising: (1) 3×IM7-SED1 fusion protein is expressed heterologously in Pichia pastoris GS115, and constructs IM7 yeast.(2)CL7-PETase fusion protein is expressed heterologously in Escherichia coli BL21 (DE3), and constructs CL7-PETase protein.(3)IM7 yeast and CL7-PETase protein are combined, and the surface display of PETase protein on Pichia pastoris is realized.The construction method of indirect surface display used in the application overcomes the disadvantage of insufficient expression of direct surface display system, and compared with free enzyme, has the characteristics of high stability, easy separation and recovery, controllable continuous operation, simple process, and the surface display enzyme is different from traditional physical or chemical immobilization method.For PET rigid substrate, surface display enzyme can more fully and effectively contact with substrate, maximum catalysis substrate, and can be used as whole-cell catalyst in the application of PET plastic degradation.

The present invention relates to a thymic tumor microenvironment antigen detection kit and its application in myasthenia gravis evaluation. The thymic tumor microenvironment antigen detection kit includes quantum dot-coupled antibody AchR, quantum dot-coupled antibody Titin, quantum dot-coupled antibody MuSK, quantum dot-coupled antibody LRP4 and quantum dot-coupled antibody RyR; quantum dot staining is performed on thymic tumor tissue sections by the kit, and different antigen staining can be performed on the same tissue section at the same time. There are differences in the expression levels of AchR, Titin, MuSK, LRP4 and RyR antigens in patients with simple thymoma, simple myasthenia gravis and thymoma combined with myasthenia gravis, and this difference can be used to distinguish the cause, course and prognosis of myasthenia gravis. The method of using quantum dots to directly carry specific antibodies eliminates the complex staining link of secondary antibodies and improves work efficiency; and observes its expression level and spatial position.

The present invention relates to a recombinant stabilized galectin 9 protein and the use thereof, and more specifically, relates to a pharmaceutical composition comprising the recombinant stabilized galectin 9 protein for prevention or treatment of rheumatoid arthritis and a bone disease. The recombinant stabilized galectin 9 protein differs from the wild-type galectin 9 protein in that the amino acids in the link region connecting two carbohydrates recognition domains (CRDs) are deleted, and the amino acids in the C-terminal CRD (CCRD) are deleted and substituted.

The invention relates to an InDel molecular marker related to immune traits of Landaise geese and application of the InDel molecular marker, and belongs to the technical field of molecular markers. The InDel molecular marker provided by the invention is located in a full-length sequence of a CNTFR gene as shown in SEQ ID No.1, and insertion of a single base T exists at the 165833rd site. The InDel molecular marker disclosed by the invention can be used for quickly and accurately distinguishing the high / low ratio of heterophilic granulocytes / lymphocytes of the Landaise geese, has the advantages of simplicity and convenience in operation and reliable result, and provides an effective molecular basis for directional breeding of immune-related traits of the Landaise geese.

The invention provides an IL-2 mutant and an application thereof. The IL-2 mutant comprises amino acid mutation at the 125th site of a protein with an amino acid sequence as shown in SEQ ID NO: 1 and amino acid mutation at at least one of the following sites: F42 or R38, the protein with the amino acid sequence as shown in SEQ ID NO: 1 is of an IL-2 wild type, the activation capacity of the IL-2 mutant on IL-2R alpha beta gamma is lower than that of the IL-2 wild type on IL-2R alpha beta gamma, and the IL-2 mutant can be used for preparing the IL-2 mutant. The activation capability of the IL-2 mutant on IL-2R beta gamma is not obviously different from the activation capability of the IL-2 wild type on IL-2R beta gamma. According to the IL-2 mutant, the cell bias is improved, CD8 + T effector cells and NK cells can be selectively activated, immunosuppression caused by activation of Treg cells is avoided, and the problem that in the prior art, the cell bias is low is effectively solved.

The invention relates to a probiotic composite product helpful for inhibiting the activity of angiotensin and a preparation method thereof. The probiotic composite product contains lactobacillus plantarum CW006 and radix puerariae powder. Different from the prior art, the lactobacillus plantarum CWO06 added in the formula of the technical scheme can hydrolyze protein through extracellular protease, reduce conversion from angiotensin I to angiotensin II and reduce hydrolysis inactivation of bradykinin, so that the effect of reducing blood pressure is achieved. The radix puerariae powder serving as an active ingredient is rich in isoflavone substances, has an inhibiting effect on a renin-angiotensin system (RAS), and has an effect of assisting in lowering blood pressure.

The application belongs to the technical field of molecular diagnosis, and particularly relates to a group of extracellular vesicle proteins as biomarkers for diagnosing abdominal aortic aneurysm and application. The application early diagnoses abdominal aortic aneurysm through determination of circulating extracellular vesicle protein markers, and provides an effective tool for diagnosis of abdominal aortic aneurysm. The extracellular vesicle protein marker is any one or two or more molecular marker combinations of interleukin-4 (IL-4), interleukin-6 (IL-6), monocyte chemotactic protein-1 (MCP-1), nerve growth factor (Neurturin) and tumor suppressor M (Oncostatin-M). The application uses proteins in extracellular vesicles as specific markers for early diagnosis of abdominal aortic aneurysm, which is a less applied field in current early diagnosis of AAA. The specific proteins in EVs may be directly related to the pathological process of AAA, and are different from conventional serum markers, and have higher specificity and sensitivity.

Analogues of PYY differing from native human PYY by substitution of Ser23 with Ala23, Glu23, Lys23, Gln23 or AIB23. Further optional features include substitutions at further positions, loss of the Tyr1 residue of native human PYY and amidation of the C-terminus. Suitable for use as pharmaceuticals for treating and preventing disorders, in particular diabetes and obesity.

A method of determining a health status of an individual, the method comprising the steps of assaying a biological sample from the individual for the positive expression of SAA1 and / or SAA2, and wherein the positive expression of the SAA1 and / or SAA2 above or below a threshold expression level in a control sample correlates with the health status of the individual.

The invention discloses an InDel molecular marker for identifying the elongation capacity of mesocotyl in rice, application and a method. The nucleotide sequence of the InDel marker is as shown in SEQ ID No. 4; the molecular marker is located at the 981 site to the 2040 site of a nucleotide sequence of SEQ ID No. 1 and is insertion and deletion of 1060 bp; the primer pair for detecting the InDel marker comprises a forward primer with a nucleotide sequence as shown in SEQ ID No. 2 and a reverse primer with a nucleotide sequence as shown in SEQ ID No. 3. The primer designed by the invention can effectively amplify specific gene segments of rice, and the specific gene segments are distinguished through agarose gel electrophoresis, so that mesocotyl length genotypes of different rice germplasms can be effectively distinguished, and identification of target genes in rice germplasm resources and breeding progenies can be conveniently and quickly realized; the labor cost is greatly reduced, the time is saved, and a foundation is laid for rice breeding work.

The present invention discloses a variant D-allulose 3-epimerase (DAEase) that is distinguished from a wild-type DAEase derived from Spirochaetales bacterium (spDAEase) by at least one amino acid sequence variation comprising substitution of an 5 amino acid residue corresponding to position 69, 119, 138, 175, 203, 208, 229, 240, or 265 of SEQ ID NO. 1; or a variant DAEase that is distinguished from a wild-type DAEase derived from Clostridium cellulolyticum (ccDAEase) by an amino acid sequence variation comprising substitution of an amino acid at position 46 and / or a truncation of C-terminal end of in SEQ ID NO. 2.

The invention belongs to the field of gene engineering, and particularly relates to a recombinant bluetongue virus with green fluorescent protein carried on an NS1 microtube as well as a construction method and application of the recombinant bluetongue virus. According to the invention, an enhanced green fluorescent protein (eGFP) gene is inserted between the 534 amino acid and the 535 amino acid of a wild type bluetongue virus non-structural protein NS1, and an NS1 recombinant bluetongue virus BTV-NS1-534 eGFP is constructed; the recombinant bluetongue virus BTV1-NS1-534eGFP can form a virus-like microtubule similar to a wild type bluetongue virus (BTV1-WT), the growth characteristics of the virus-like microtubule are not obviously different from those of the BTV1-WT, and the recombinant bluetongue virus BTV1-NS1-534eGFP can correctly express enhanced green fluorescent protein; the method can be used for tracing research of NS1 protein after BTV infects cells, and can also be used for virus neutralization experiment of BTV, visual quantitative detection of virus content and the like.

The invention relates to siRNA as well as a conjugate and application thereof, and belongs to the technical field of molecular biology and biological medicine. The siRNA comprises a positive-sense strand and an antisense strand. The conjugate comprises an aptamer and siRNA (small interfering Ribonucleic Acid). The siRNA and the conjugate provided by the invention are good in targeting property and high in safety, enter cancer cells (such as liver cancer cells) without the help of an exogenous transfection agent, and realize efficient knock-down of an immune checkpoint Nectin-2, so that the anti-tumor reaction of T cells is activated, and the siRNA and the conjugate are used for precise immunotherapy of tumors (such as liver cancer). The conjugate provided by the invention can be autonomously delivered to tumor cells without a transfection agent, quickly enters cytoplasm of the tumor cells without the help of lipidosome, polymer or viral vector, and generates a functional effect. The delivery strategy is high in safety, has unique practical value, and is different from a current mainstream delivery system in the RNA interference field.

The present invention belongs to the field of biological genetic engineering, and specifically relates to a Magnaporthe oryzae MoPCP1 gene and its application. The full-length sequence of the Magnaporthe oryzae MoPCP1 gene is shown in SEQ ID NO.1, the cDNA sequence is shown in SEQ ID NO.2, and the amino acid sequence of the encoded protein is shown in SEQ ID NO.3. Experiments show that after replacing the Magnaporthe oryzae MoPCP1 gene with the hygromycin resistance gene, the obtained Magnaporthe oryzae knockout mutant has obvious changes in vegetative growth ability, appressorium formation ability, and conidia morphology and size compared with the wild-type Magnaporthe oryzae, and there are obvious differences in the response to external environmental factors; the pathogenicity experiment shows that MoPCP1 the deletion of the gene significantly reduces the pathogenicity of Magnaporthe oryzae, indicating that MoPCP1 the gene plays a significant role in regulating the pathogenicity of Magnaporthe oryzae. The MoPCP1 gene and its application provided by the present invention play an important role in the pathogenicity of Magnaporthe oryzae, providing a new direction for further using this gene to control Magnaporthe oryzae.

The invention belongs to the technical field of biological medicines, and particularly relates to an intestinal microbial marker for distinguishing a bile duct cell carcinoma patient from a healthy person and application of the intestinal microbial marker. The invention provides an enteric microbiological marker for distinguishing a bile duct cell carcinoma patient from a healthy person. The enteric microbiological marker consists of 23 enteric microbiological strains. The intestinal microbial marker disclosed by the invention realizes good distinguishing ability in cholangiocellular carcinoma and healthy people. And the feasibility and applicability of the distinguishing model are verified in cross-regional samples in China. In addition, the distinguishing model achieves good disease specificity in a common data set queue of 11 diseases from the world.

A uridine diphosphate-N-difluoroacetylglucosamine, a preparation method therefor and a use thereof. The uridine diphosphate-N-difluoroacetylglucosamine has a similar chemical structure to the natural substrate UDP-GlcNAc, the difference being that the 2-position N-acetyl group thereof is replaced by an N-difluoroacetyl group. The preparation method is as follows: (1) preparing difluoroacetylglucosamine; (2) using difluoroacetylglucosamine as a substrate to prepare uridine diphosphate-N-difluoroacetylglucosamine. A novel, highly active, non-hydrolyzable and artificially synthesizable artificial donor sugar uridine diphosphate-N-difluoroacetylglucosamine (UDP-GlcNDFA) is provided. Compared with the existing donor sugar UDP-GlcNTFA, UDP-GlcNDFA has higher catalytic activity for glycosyltransferases, is stable and not easily hydrolyzed, and can be used as a donor substrate for chemoenzymatic synthesis of heparin oligosaccharide scaffolds, heparin oligosaccharide intermediates and heparin oligosaccharides, as well as hyaluronic acid oligosaccharides, glycoconjugates (glycosylated polypeptides) and polysaccharide antigens.

This invention relates to the field of veterinary biological products, specifically to a live attenuated strain of Brucella brucellosis RB39, its applications, vaccines, antigens, and kits. The live attenuated Brucella brucellosis RB39 of this invention can be used to prepare a highly safe vaccine that can be injected into pregnant animals and provides good immunoprotection. Furthermore, this vaccine is suitable for immunization of multiple animal species. In addition, based on the live attenuated Brucella brucellosis RB39 of this invention, an antigen can be prepared to identify Brucella brucellosis antibodies, effectively distinguishing between vaccine immunization and natural infection, providing a scientific basis for brucellosis prevention and control.

The invention relates to the technical field of molecular markers, and particularly provides a molecular marker primer combination for identifying large fragment deletion of a Camellia tonkinensis CdS-RNase gene and application of the molecular marker primer combination. The primer combination provided by the invention can be used for distinguishing and identifying the camellia tonkinensis normally containing the CdS-RNase gene and the camellia tonkinensis with large fragment deletion of the CdS-RNase gene (CdSm < 2 >-RNase), and interspecific identification is realized in the aspect of breeding. According to the method, the identification efficiency of different types of CdS-RNase genes can be improved, and the camellia oleifera breeding process can be further accelerated.

The present invention relates to the technical field of bioinformatics, and specifically provides a method and system for predicting the pathogenicity of splicing variants based on contrastive learning. Only the DNA sequence information before and after the variant of the splicing variant is used, greatly simplifying the feature input of the model. The embedded sequence information is obtained through a DNA pre-trained model and then processed by a contrastive learning module. For variants that are pathogenic after mutation, the contrastive learning module processes them into more different embeddings; for variants that are benign after mutation, the difference between the two is reduced, making it easier for the classifier to capture the subtle differences, thereby achieving efficient pathogenicity prediction. The present invention directly learns from the sequence, reduces the model bias caused by different feature selections, avoids the additional errors introduced in biological feature calculations, and the performance on the blind test set shows that the model can accurately predict pathogenic variants, and at the same time has balance, good generalization and robustness.

The present invention relates to a new variant of EPO. In this study, the inventors identified a particular EPO differing from kidney-type EPO due to a different glycosylation pattern in patients with different diseases (for example idiopathic erythrocytosis, liver / kidney disorder, tumors...). This new EPO is similar to pre-term newborn EPO produced by the liver that differs from the normal EPO produced from renal interstitial cells due to different post-translational modifications (glycosylations). This new EPO shows an increased biological activity via activation of the EPO receptor (EPOR), that can explain the origin of erythrocytosis. The detection of this specific liver-like EPO could be used as a diagnostic tool to better adapt and follow the treatments of erythrocytosis patients or in other diseases associated with the overproduction of red blood cells. Thus, the invention relates to a specific EPO protein which differs from the EPO with kidney-type glycosylation pattern.

The present disclosure relates to an assay method for detection of target nucleic acid. The method includes immobilizing a guide RNA (gRNA) to an immobilization surface; complexing a Cas enzyme to the gRNA; adding a target nucleic acid; labeling the target nucleic acid; detecting the target nucleic acid without amplification; and determining one or more results based on the detected target nucleic acid via a reader.